Founder and Managing Partner, Frazier Healthcare Ventures
Founder and CEO, Acme Packet
President and CEO of the Central Indiana Corporate Partnership
Professor, Michigan State University
Founder and Chairman, Sycamore Networks
CEO and co-founder of BoostSuite
CEO and Co-Founder, Tamr
Founder and CEO, Acme Packet
Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms.
The FDA approved the drug, lasmiditan... Read more »
Congrats to this year’s Nobel Prize winners in medicine… although, we have to ask: For the US researchers who are honored, isn’t there something crushing about a call in the middle of the night from Sweden, interrupting a dream about... Read more »
Sixteen years ago, Kim Witczak’s husband died by his own hand, turning her world upside down. He had just begun taking an antidepressant off-label for insomnia, and she believes an undisclosed side effect of the drug drove him to suicide. Compelled... Read more »
Five years ago, the big tech incubator Y Combinator started to welcome life sciences companies into its sizable startup classes, which had previously nurtured entrepreneurs in information technology almost exclusively.
That opening to biotech startups in 2014 was controversial at the... Read more »
Oxygen’s importance in cellular processes has long been known. But the work to understand how cells sense and adapt to changes in oxygen levels has led to medical insights and potential treatments for anemia, cancer, and more—and today, it has turned... Read more »
This summer Nestlé Health Science sold Prometheus Laboratories, a gastrointestinal disease diagnostics unit it had acquired eight years prior, to a low-profile San Diego biotech called Precision IBD.
About a month ago, Precision—a drug and diagnostic developer that’s focused, as... Read more »
It’s been a strange up and down ride for PARP inhibitors, a relatively new class of cancer drugs.
Named for the tumor protein they target, PARPs rebounded after a big clinical setback in 2011 and have been at the center of... Read more »
The European Society for Medical Oncology meeting has wrapped up in Barcelona, the last major clinical cancer conference until December’s annual ASH meeting for blood diseases. We’ve highlighted a few top stories for you.
Amid all the fuss over cell, gene,... Read more »
In the past three years, Dova Pharmaceuticals has completed a company launch, gone public, and won its first drug approval. Now the biotech is in line to be acquired by Swedish Orphan Biovitrum (Sobi).
According to deal terms announced Monday, Dova... Read more »
Lung injuries linked to electronic cigarettes have topped 800 cases, including 12 deaths, according to the Centers for Disease Control and Prevention. Public health officials aren’t sure whether the injuries are from legally sold products made by companies such as... Read more »
Boston, San Francisco, and a few other metro areas might dominate the US life sciences, but some weeks, all bio-related eyes are on the nation’s capital. Health concerns about vaping continue to mount, and the feds could get involved. Meanwhile, try... Read more »
With the 2020 election just over a year away, House Speaker Nancy Pelosi (D-CA) has unveiled the Democratic Party’s answer to public discontent over high prescription drug prices.
A preview of the plan was leaked last week. Today’s announcement doesn’t... Read more »
For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical meeting in Barcelona this week was any indication, more help could be on the... Read more »
The first details of the long-awaited House Democrat plan to lower drug prices leaked out Monday night, with elements that have long been anathema to the biopharma industry and its supporters in Washington.
While the world digested the details Tuesday, however,... Read more »
This year’s Lasker Awards, the US’s most prestigious biomedical honor, are going to five scientists whose work led to a critical breast cancer treatment and significant basic research advances that have helped pave the way for immunotherapy.
H. Michael Shepard, Dennis... Read more »
The treatment landscape for lung cancer has shifted significantly over the past few years, and more changes could be on the way. At the World Conference on Lung Cancer in Barcelona this weekend a number of drug makers trotted out... Read more »
Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have... Read more »
The ways in which robocallers try to dupe us are becoming almost as plentiful as the frequency of the calls.
An unknown phone number was once all scammers needed to trick the average person into picking up the call. Now,... Read more »
You might be camping, barbecuing, or sleeping on Monday. It’s Labor Day, after all. But in Paris, this cardiologist will be in a conference center, walking an audience through a slide deck packed with Phase 3 data for a new cholesterol-lowering... Read more »
[Updated 8/26/19, 10:30am. See below.] Remember when the new wave of expensive cholesterol-lowering drugs—known as PCSK9 inhibitors—was supposed to give the healthcare system a financial heart attack?
Far from it. Four years after approval the two PCSK9 blockers... Read more »
An experimental GlaxoSmithKline treatment for multiple myeloma has achieved the main goal of a key study, and the drug maker plans to file for regulatory approval by the end of this year.
GlaxoSmithKline (NYSE: GSK) said Friday that treatment with... Read more »
Biotech news tends to slow down in August but the past seven days have been busy for regulatory decisions. Three drugs and two devices won FDA nods.
Not all companies were as fortunate. Several biotechs reported failed clinical trials or unfavorable... Read more »
Xconomy Insight · Webinar
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.
Sponsored · Whitepaper
Implementing electronic solutions for risk mitigation
XiltriX
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
Tax credits help tech innovators attract capital, fuel growth
Wisconsin Economic Development Corporation
Professor at the University of North Carolina at Chapel Hill
CEO and co-founder of BoostSuite
President, CEO, and Chairman of the Board of SciQuest
President of the Council for Economic Development (CED)
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Vice President, Carolinas HealthCare System
CEO of G1 Therapeutics
Retired CEO of ShopperTrak RCT Corporation
Vice Provost and Director of the Innovation and Entrepreneurship Initiative at Duke University
Managing Partner at Pappas Ventures
Founder and CEO of Brooks Bell Inc.
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
